$17.23
3.85% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US89422G1076
Symbol
TVTX

Travere Therapeutics Inc Stock price

$17.23
+1.91 12.47% 1M
-3.42 16.56% 6M
-0.19 1.09% YTD
+8.18 90.39% 1Y
-11.19 39.37% 3Y
-2.41 12.27% 5Y
-7.87 31.35% 10Y
+17.01 7,557.78% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.69 3.85%
ISIN
US89422G1076
Symbol
TVTX
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.6b
Net debt
$60.3m
Cash
$319.5m
Shares outstanding
89.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.6 | 3.6
EV/Sales
4.8 | 3.7
EV/FCF
negative
P/B
46.9
Financial Health
Equity Ratio
9.9%
Return on Equity
-544.3%
ROCE
-46.7%
ROIC
-90.4%
Debt/Equity
11.6
Financials (TTM | estimate)
Revenue
$333.9m | $427.3m
EBITDA
$-122.1m | $-88.5m
EBIT
$-170.7m | $-119.2m
Net Income
$-169.1m | $-101.9m
Free Cash Flow
$-157.3m
Growth (TTM | estimate)
Revenue
87.9% | 83.3%
EBITDA
56.0% | 58.7%
EBIT
46.0% | 53.5%
Net Income
-15.9% | 68.3%
Free Cash Flow
58.9%
Margin (TTM | estimate)
Gross
96.9%
EBITDA
-36.6% | -20.7%
EBIT
-51.1%
Net
-50.6% | -23.8%
Free Cash Flow
-47.1%
More
EPS
$-1.9
FCF per Share
$-1.8
Short interest
12.0%
Employees
385
Rev per Employee
$610.0k
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Travere Therapeutics Inc forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
334 334
88% 88%
100%
- Direct Costs 10 10
10% 10%
3%
323 323
92% 92%
97%
- Selling and Administrative Expenses 236 236
5% 5%
71%
- Research and Development Expense 210 210
5% 5%
63%
-122 -122
56% 56%
-37%
- Depreciation and Amortization 49 49
24% 24%
15%
EBIT (Operating Income) EBIT -171 -171
46% 46%
-51%
Net Profit -169 -169
16% 16%
-51%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Positive
Seeking Alpha
14 days ago
Travere Therapeutics has successfully executed a significant restructuring to recover from previous setbacks and improve its financial health. It has built a compact pipeline of kidney therapy drugs with several having blockbuster potential. Its approved FILSPARI in treatment of IgAN is enjoying rapid growth.
Neutral
Business Wire
14 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 45,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's...
Neutral
Seeking Alpha
19 days ago
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Nivi Nehra - Corporate Participant e - Corporate Participant V - Corporate Participant i - Corporate Participant c - Corporate Participant P - Corporate Pa...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 385
Founded 2008
Website travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today